Overall rank by patents
#32,000
Across all tracked assignees
USPTO 2015–2025 USPTO PatentsView Foreign Corporation
Immunicum AB
USPTO PatentsView assignee record - 8 granted patents across 4 technology areas, active 2015–2020. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: C12N (MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA).
8
Total patents granted
4
CPC technology areas
12.5
Avg claims per patent
-86%
5-year filing velocity
The verdict
Immunicum holds 8 US patents across 4 technology areas, rank #32,000 of 50,000 tracked assignees.
- #32,000
- of 50,000 US assignees by volume
- Top 90%
- by Innovation Score (22.2/100)
- 12.5
- avg claims per patent
- -86%
- filing velocity, last 5 yrs
Portfolio overview
Immunicum AB has been granted 8 US utility patents between 2015 and 2020, placing Immunicum AB at rank #32,000 across all assignees tracked by PlainPatent. This portfolio spans 4 distinct Cooperative Patent Classification (CPC) subclasses, averaging 12.5 claims per patent with primary concentration in C12N (MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA). As a Foreign Corporation, Immunicum AB is one of the more focused assignees in the PatentsView dataset. By volume, Immunicum sits between Imagine Optic (8 patents, rank #31,996) and Incucomm, Inc. (8 patents, rank #32,004) - the closest US assignees by grant volume. The composite Innovation Score of 22.2/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Between 2020 and 2025 the company received 1 grants, compared with 7 in the 2015–2019 window, a -86% shift in five-year velocity. A cooling filing rate may reflect portfolio consolidation, shifting priorities, or reduced R&D throughput. The Foreign Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. Immunicum AB's 12.5 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while specialization in 4 subclasses reflects a tightly scoped invention area. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Immunicum AB against peers pursuing similar technology classes.
Who files at Immunicum's volume?
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
- Imagine Optic
IMAGINE OPTIC
8 patents
- Imberatek
IMBERATEK, LLC
8 patents
- IMC TOYS
IMC TOYS, S.A.
8 patents
- Imdss Solutions
IMDSS Solutions LLC
8 patents
- Immuta
IMMUTA, INC.
8 patents
- Improbed AB
IMPROBED AB
8 patents
- Imris
IMRIS, Inc.
8 patents
- Incucomm
INCUCOMM, INC.
8 patents
- Immunicum AB ◀
IMMUNICUM AB
8 patents
What this shows Immunicum holds 8 patents at rank #32,000, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Companies ranked near Immunicum
By rank, the assignees closest to #32,000 in granted patent volume.
Leaders in C12N (Microorganisms OR Enzymes)
Other assignees with the most granted patents in Immunicum's primary technology class.
- Monsanto Technology Llc 1,335 in class
- The Regents Of The University Of California 1,161 in class
- Novozymes A/s 656 in class
- Immatics Biotechnologies Gmbh 647 in class
- Pioneer Hi-bred International, Inc. 623 in class
- President And Fellows Of Harvard College 594 in class
- Massachusetts Institute Of Technology 541 in class
- The Trustees Of The University Of Pennsylvania 537 in class
Immunicum's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
22 Top 90% higher than 10% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2015 | 2 | 25.0% |
| 2016 | 2 | 25.0% |
| 2017 | 2 | 25.0% |
| 2018 | 1 | 12.5% |
| 2020 | 1 | 12.5% |
Which technologies does Immunicum AB patent most?
Top 4 of 4 technology areas
Patent Moat Analysis
Portfolio Volume Light
Tech Breadth Specialized
Claim Depth Standard
Velocity Declining
Frequently Asked Questions
How many patents does Immunicum AB hold?
Immunicum AB holds 8 US granted patents filed between 2015 and 2020, spanning 4 technology areas.
What is Immunicum AB's Innovation Score?
Immunicum AB has an Innovation Score of 22.2 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does Immunicum AB focus on?
Immunicum AB's top technology area is C12N (MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA) with 8 patents. The company has filed patents in 4 CPC subclasses total.
Is Immunicum AB's patent filing rate increasing or decreasing?
Immunicum AB's recent filing velocity is -86% compared to the prior five-year period. Filing activity has slowed relative to earlier years.
What does claim depth mean for Immunicum AB's patents?
Immunicum AB's patents average 12.5 claims each. This falls within the standard range, providing solid legal coverage.
How is the Immunicum AB patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.
How to use this portfolio
Immunicum's 8 grants land it in the top 90% by Innovation Score, but volume alone doesn't tell you where the strength sits.
- Read that count against the largest US assignees before treating it as dominance - Immunicum ranks #32,000 of 50,000. Top 50 holders
- Most of this portfolio concentrates in C12N - see who else leads that technology area. C12N leaders
- Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.